3 Fantastic Growth Opportunities for Eli Lilly That Go Beyond GLP-1 Drugs

If you're buying Eli Lilly (NYSE: LLY) stock today, odds are, it's because of its highly popular and successful GLP-1 drugs, Mounjaro and Zepbound. The former is approved to treat diabetes, while the latter is approved for weight loss. These drugs have generated billions in revenue for the company, and they are still in their early growth stages.But while GLP-1 may be the flashiest and most exciting reason to invest in Eli Lilly, the business is far bigger than that. There are three other amazing growth opportunities for the business to tap into in the long run, which, if they pay off, could make the seemingly expensive stock look like a steal of a deal in the future.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool